Overview

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with chronic hepatitis C infection.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Caffeine
Interferons
Midazolam
Protease Inhibitors
Ribavirin
Tenofovir
Tolbutamide